Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on tough lymphoma in early trial

NCT ID NCT05741359

Recruiting now Disease control Sponsor: Bioray Laboratories Source: ClinicalTrials.gov ↗

First seen Jan 04, 2026 · Last updated May 18, 2026 · Updated 21 times

Summary

This study tests a new treatment called BRL-201 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, which are modified in a lab to better find and attack cancer cells. The main goals are to check safety and find the best dose in about 12 to 18 adults.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA,B CELL are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Zhejiang University

    RECRUITING

    Hangzhou, Zhejiang, China

    Contact

  • Tianjin Institute of Hematology

    RECRUITING

    Tianjin, Tianjin Municipality, China

    Contact

  • Wuhan Union Hospital

    RECRUITING

    Wuhan, Hubei, China

    Contact

Conditions

Explore the condition pages connected to this study.

NON-HODGKIN LYMPHOMA,B CELL